Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth (2009)
Sequence: ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-Cya
| Experiment Id | EXP000167 |
|---|---|
| Paper | Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth |
| Peptide | MPGNLS (parent MPG) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 5 µg siRNA (0.25 mg/kg) |
| Mixing Ratio | 20:1 peptide:siRNA |
| Formulation Format | MPGNLS/Cyc-B1 siRNA nanoparticles |
| Formulation Components | |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | PC3 xenograft nude mice |
| Administration Route | intratumoral |
| Output Type | tumor growth inhibition + target mRNA reduction |
| Output Value | No significant inhibition (7–10% deviation); Cyc-B1 mRNA ↓~7% |
| Output Units | |
| Output Notes | |
| Toxicity Notes | |
| Curation Notes |